DE60024360D1 - Verwendungen und Zusammensetzungen zur Behandlung von primären und sekundären Tumoren des Zentralnervensystems (ZNS) - Google Patents

Verwendungen und Zusammensetzungen zur Behandlung von primären und sekundären Tumoren des Zentralnervensystems (ZNS)

Info

Publication number
DE60024360D1
DE60024360D1 DE60024360T DE60024360T DE60024360D1 DE 60024360 D1 DE60024360 D1 DE 60024360D1 DE 60024360 T DE60024360 T DE 60024360T DE 60024360 T DE60024360 T DE 60024360T DE 60024360 D1 DE60024360 D1 DE 60024360D1
Authority
DE
Germany
Prior art keywords
nervous system
central nervous
cns
compositions
primary
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60024360T
Other languages
English (en)
Other versions
DE60024360T2 (de
Inventor
Rudiger Stendel
Rolf Wilhelm Pfirrmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ed Geistlich Soehne AG fuer Chemische Industrie
Original Assignee
Ed Geistlich Soehne AG fuer Chemische Industrie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27538049&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60024360(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ed Geistlich Soehne AG fuer Chemische Industrie filed Critical Ed Geistlich Soehne AG fuer Chemische Industrie
Application granted granted Critical
Publication of DE60024360D1 publication Critical patent/DE60024360D1/de
Publication of DE60024360T2 publication Critical patent/DE60024360T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2006—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
DE60024360T 1999-06-04 2000-06-05 Verwendungen und Zusammensetzungen zur Behandlung von primären und sekundären Tumoren des Zentralnervensystems (ZNS) Expired - Lifetime DE60024360T2 (de)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US13742199P 1999-06-04 1999-06-04
US137421P 1999-06-04
US15105099P 1999-08-27 1999-08-27
US151050P 1999-08-27
US16768199P 1999-11-29 1999-11-29
US167681P 1999-11-29
US17460700P 2000-01-05 2000-01-05
US174607P 2000-01-05
US18220000P 2000-02-14 2000-02-14
US182200P 2000-02-14

Publications (2)

Publication Number Publication Date
DE60024360D1 true DE60024360D1 (de) 2006-01-05
DE60024360T2 DE60024360T2 (de) 2006-06-08

Family

ID=27538049

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60024360T Expired - Lifetime DE60024360T2 (de) 1999-06-04 2000-06-05 Verwendungen und Zusammensetzungen zur Behandlung von primären und sekundären Tumoren des Zentralnervensystems (ZNS)

Country Status (7)

Country Link
US (4) US6479481B1 (de)
EP (2) EP1595543B1 (de)
JP (2) JP2001010976A (de)
AT (1) ATE311179T1 (de)
CA (1) CA2310534C (de)
DE (1) DE60024360T2 (de)
ES (2) ES2251939T3 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050124608A1 (en) * 2001-04-03 2005-06-09 Redmond H. P. Treatment of cancers
US6479481B1 (en) 1999-06-04 2002-11-12 Ed. Geistlich Soehne Ag Fur Chemische Industrie Methods and compositions for treating primary and secondary tumors of the central nervous system (CNS)
US20060199811A1 (en) * 1997-07-31 2006-09-07 Pfirrmann Rolf W Method of treatment for preventing or reducing tumor growth in the liver of patient
US8304390B2 (en) * 1997-07-31 2012-11-06 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Method of treatment for preventing or reducing tumor growth in the liver of patient
US7151099B2 (en) 1998-07-31 2006-12-19 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Use of taurolidine and/or taurultam for treatment of abdominal cancer and/or for the prevention of metastases
US20030027818A1 (en) * 2001-04-03 2003-02-06 Redmond H. Paul Treatment of cancers
US20070275955A1 (en) * 1997-07-31 2007-11-29 Ed. Geistlich Soehne Ag Method of treating tumors
US20050096314A1 (en) * 2001-04-03 2005-05-05 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of cancers with methylol-containing compounds and at least one electrolyte
US7892530B2 (en) * 1999-06-04 2011-02-22 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of tumor metastases and cancer
US6821968B2 (en) * 2001-09-26 2004-11-23 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Stable taurolidine electrolyte solutions
US20020098164A1 (en) * 2000-10-27 2002-07-25 Redmond H. Paul Treatment of tumor metastases and cancer
US7345039B2 (en) * 1999-06-04 2008-03-18 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Enhancement of effectiveness of 5-fluorouracil in treatment of tumor metastases and cancer
US8030301B2 (en) * 1999-06-04 2011-10-04 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of cancers with methylol-containing compounds and at least one electrolyte
US20030225067A1 (en) * 1999-06-04 2003-12-04 Ruediger Stendel Microdialysis methods and applications for treatment and/or prophylaxis of tumors and/or infections in the central nervous system (CNS) and/or in other parenchymal organs
US6429224B1 (en) 1999-12-06 2002-08-06 Rhode Island Hospital, A Lifespan Partner Use of taurolidine to treat tumors
CN100519525C (zh) * 1999-12-06 2009-07-29 葛兰素集团有限公司 芳香砜类及其医疗用途
EP1797884B1 (de) * 1999-12-06 2013-09-11 Geistlich Pharma AG Taurolidin oder Taurultam zur Verwendung bei der Behandlung von Tumoren der Prostata, des Kolons, der Lungen und von wiederkehrendem Glioblastoma multiforme.
CA2363973C (en) * 2000-11-28 2009-03-10 Ed. Geistlich Sohne Ag Fur Chemische Industrie Enhancement of effectiveness of 5-fluorouracil in treatment of tumor metastases and cancer
CA2441016A1 (en) * 2001-03-15 2002-09-26 Paul Calabresi Taurine compounds
EP1450814B1 (de) 2001-10-01 2016-11-30 Geistlich Pharma AG Verfahren zur hemmung von metastasen
JP2003119136A (ja) * 2001-10-10 2003-04-23 Mutsuyuki Kochi 悪性細胞の分化誘導剤組成物とその使用
JP5346148B2 (ja) * 2003-03-28 2013-11-20 エー・デー・ガイストリヒ・ゾーネ・アクチェンゲゼルシャフト・フュール・ヒェーミシェ・インダストリー 抗新生物性組成物および治療方法
US8236794B2 (en) 2003-09-29 2012-08-07 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of mesothelioma
JP2007537200A (ja) * 2004-05-14 2007-12-20 ハンス−ディートリヒ・ポラシェグ タウロリジン製剤及び投与：細菌マイクロフィルム形成に対する治療処置及び抗菌保護
WO2007019065A2 (en) * 2005-08-04 2007-02-15 Oklahoma Medical Research Foundation Adjuvant chemotherapy for anaplastic gliomas
US20100040667A1 (en) * 2006-09-07 2010-02-18 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Method of treating bone cancer
US20170196875A1 (en) * 2016-01-11 2017-07-13 Cormedix Inc. Therapeutic nanoparticles for the treatment of neuroblastoma and other cancers
US20190381060A1 (en) * 2016-01-11 2019-12-19 Cormedix Inc. Taurolidine treatment for myc-expressing tumors in mammalian bodies
US11541061B2 (en) 2016-01-11 2023-01-03 Cormedix Inc. Neuroblastoma treatment with taurolidine hydrolysis products
CN105943522B (zh) * 2016-05-19 2019-06-21 中国医学科学院基础医学研究所 氯福克酚用于制备治疗人神经胶质瘤的药物的用途
KR101880015B1 (ko) * 2017-12-08 2018-07-19 아주대학교산학협력단 인터페론 감마를 유효성분으로 함유하는 신경섬유육종 예방 또는 치료용 조성물
US11738120B1 (en) 2022-04-14 2023-08-29 Cormedix Inc. Synthesis of taurolidine, purity profiles and polymorphs

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8328111D0 (en) 1983-10-20 1983-11-23 Geistlich Soehne Ag Chemical compounds
US5210083A (en) * 1986-07-17 1993-05-11 Ed. Geistlich Sohne A.G. Fur Chemische Industrie Pharmaceutical compositions
GB8617482D0 (en) 1986-07-17 1986-08-28 Geistlich Soehne Ag Pharmaceutical composition
GB9005856D0 (en) * 1990-03-15 1990-05-09 Geistlich Soehne Ag Compositions
GB9015108D0 (en) 1990-07-09 1990-08-29 Geistlich Soehne Ag Chemical compositions
US5416091A (en) * 1990-12-18 1995-05-16 Burroughs Wellcome Co. Agents for potentiating the effects of antitumor agents and combating multiple drug resistance
JP3580867B2 (ja) * 1994-09-07 2004-10-27 株式会社東芝 医療用ゾンデ
GB9600426D0 (en) * 1996-01-10 1996-03-13 Ed Geistlich Sohne A G Compositions
EP0981761A1 (de) * 1997-05-15 2000-03-01 Regents Of The University Of Minnesota Schaltkreis mit einer Einheit zum Testen von Verbindungenvon Bilderzeugungdurch magnetische Resonanz zur gezielten Medikamentenabgabe an einen lebenden Patienten
GB9716219D0 (en) * 1997-07-31 1997-10-08 Geistlich Soehne Ag Prevention of metastases
US6479481B1 (en) 1999-06-04 2002-11-12 Ed. Geistlich Soehne Ag Fur Chemische Industrie Methods and compositions for treating primary and secondary tumors of the central nervous system (CNS)
CA2302720C (en) 1999-03-29 2009-07-14 Ed Geistlich Sohne Ag Fur Chemische Industrie Anticoagulant/sterilizing compositions and methods
US20020098164A1 (en) * 2000-10-27 2002-07-25 Redmond H. Paul Treatment of tumor metastases and cancer
US6429224B1 (en) * 1999-12-06 2002-08-06 Rhode Island Hospital, A Lifespan Partner Use of taurolidine to treat tumors

Also Published As

Publication number Publication date
EP1595543A3 (de) 2006-08-02
ES2251939T3 (es) 2006-05-16
ES2532259T3 (es) 2015-03-25
JP2008195726A (ja) 2008-08-28
US20030064942A1 (en) 2003-04-03
CA2310534A1 (en) 2000-12-04
US20100048542A1 (en) 2010-02-25
ATE311179T1 (de) 2005-12-15
US20030195198A1 (en) 2003-10-16
EP1595543B1 (de) 2014-12-17
US7638511B2 (en) 2009-12-29
US8202860B2 (en) 2012-06-19
US6479481B1 (en) 2002-11-12
US6815441B2 (en) 2004-11-09
DE60024360T2 (de) 2006-06-08
EP1066830A2 (de) 2001-01-10
EP1066830B1 (de) 2005-11-30
EP1595543A2 (de) 2005-11-16
EP1066830A3 (de) 2002-10-16
CA2310534C (en) 2011-01-18
JP2001010976A (ja) 2001-01-16

Similar Documents

Publication Publication Date Title
DE60024360D1 (de) Verwendungen und Zusammensetzungen zur Behandlung von primären und sekundären Tumoren des Zentralnervensystems (ZNS)
DE60235083D1 (de) Substituierte tetracyclin-verbindungen zur behandlung von malaria
CY1105460T1 (el) Παραγωγα ακετυλενιου που εχουν mlgur 5 ανταγωνιστικη δραση
BR9811482A (pt) Derivados de 1-(n-fenilaminoalquil)-piperazina substituìda na posição 2 do anel fenìlico
PL342078A1 (en) Inhibition of raf kinase using symmetrical and dissymmetrical substituted dimethylureas
ATE412642T1 (de) Inhibitoren von p-38-kinase
HK1026691A1 (en) Substituted benzimidazoles and their use for treating retroviral infection
HK1042251A1 (en) Omega-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
DE60027913D1 (de) 5-beta-sapogenin und pseudosapogeninderivate und ihre verwendung zur behandlung von demenz
ATE227277T1 (de) Isoxazoline derivate und ihre verwendung als antimikroben
DE60014136D1 (de) Sapogenin derivate zur behandlung von kognitiven störungen
ATE251624T1 (de) Granulatimide-derivate zur behandlung von krebs
DE69307674T2 (de) HIV-Proteaseinhibitoren und ihre Verwendung zur Behandlung von AIDS
MX9604762A (es) Nuevas sulfonamidas y procedimiento para su preparacion.
ATE352307T1 (de) Zusammensetzung zur behandlung von tumoren oder krebs, welche fluorouracil und ein methylol übertragungsmittel enthält
ID25478A (id) Agonis 5-ht1f
ATE267018T1 (de) Verwendung von peptidverbindungen zur behandlung von sle
ES2135383T3 (es) Pirido(3,4-b)pirrolo(1,2-e)(1,4,5)oxadiazepinas y compuestos analogos relacionados, un procedimiento para su preparacion y su uso como medicamentos.
DE69827706D1 (de) 5-(Heteroaryl)alkyl)-3-oxo-pyrido(1,2-a)benzimidazol-4-carboxamid (PBI) Derivate zur Behandlung von Störungen des zentralen Nervensystems
BG105549A (en) Use of n-substituted azabicycloalkane derivatives for treating diseases of the central nervous system
DE60111571D1 (de) Verwendung von anethol-dithiolethion zur vorbeugung und behandlung der sehnentoxizität
EA200200656A1 (ru) НОВЫЕ ТЕРАПЕВТИЧЕСКИЕ КОМБИНАЦИИ (S)-2-(БЕНЗИЛАМИНОМЕТИЛ)-2,3,8,9-ТЕТРАГИДРО-7H-1,4-ДИОКСИН [2,3-е]ИНДОЛ-8-ОНА И НЕЙРОЛЕПТИКОВ ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРЕДОТВРАЩЕНИЯ ПСИХОТИЧЕСКИХ РАССТРОЙСТВ
ES2072334T3 (es) Derivados de 4,5,5a,6-tetrahidro-3h-isoxazolo(5,4,3-kl)acridinas, un procedimiento para su preparacion y su uso como medicamentos.
DE69503635T2 (de) Pyrrolidinderivate zur behandlung von cck und gastrin-abhängigen erkrankungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition